AXIS Capital Holdings Limited (AXS) Q1 2025 Earnings Call Transcript
AXIS Capital Holdings Limited (NYSE:AXS ) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Cliff Gallant - Head, Investor Relations Vince Tizzio - President & Chief Executive Officer Pete Vogt - Chief Financial Officer Conference Call Participants Andrew Kligerman - TD Securities Christian Getzoff - Wells Fargo Meyer Shields - KBW Andrew Andersen - Jefferies Charlie Lederer - BMO Josh Shanker - Bank of America Operator Good day, and welcome to the First Quarter 2025 AXIS Capital Earnings Conference Call. All participants will be in listen-only mode.
AXIS Capital Q1 Earnings Beat Estimates on Higher Investment Income
AXS' first-quarter results reflect solid underwriting income, improved investment income, and higher premiums across the segments, offset by escalating expenses.
Here's What Key Metrics Tell Us About Axis Capital (AXS) Q1 Earnings
While the top- and bottom-line numbers for Axis Capital (AXS) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Axis Capital (AXS) Q1 Earnings Beat Estimates
Axis Capital (AXS) came out with quarterly earnings of $3.17 per share, beating the Zacks Consensus Estimate of $2.64 per share. This compares to earnings of $2.57 per share a year ago.
Axis Capital (AXS) Reports Next Week: Wall Street Expects Earnings Growth
Axis Capital (AXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AXS vs. CB: Which Stock Is the Better Value Option?
Investors interested in stocks from the Insurance - Property and Casualty sector have probably already heard of Axis Capital (AXS) and Chubb (CB). But which of these two companies is the best option for those looking for undervalued stocks?
Are Investors Undervaluing Axis Capital Holdings (AXS) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Axsome: The Alzheimer's Agitation Program For AXS-05
Axsome's AXS-05 shows strong efficacy in treating Alzheimer's Disease Agitation, with significant CMAI score reductions in multiple Phase 3 trials. The FDA has greenlit Axsome to submit an sNDA for AXS-05 without requiring new trials, based on robust existing data. AXS-05 demonstrates a favorable safety profile with low discontinuation rates due to adverse events, unlike competitors such as AVP-786 and brexpiprazole.
AXS Stock Near 52-Week High: A Signal for Investors to Hold Tight?
AXIS Capital gains from a well-performing specialty insurance, reinsurance as well as the accident and health portfolio.
Axis Capital (AXS) Up 3.8% Since Last Earnings Report: Can It Continue?
Axis Capital (AXS) reported earnings 30 days ago. What's next for the stock?
AXS Stock Trading at Discount to Industry at 1.38X: Time to Hold?
AXIS Capital stock is poised to gain from a well-performing specialty insurance, reinsurance as well as the accident and health portfolio.
Axsome Settling Teva Patent Litigation Is Another Positive Catalyst -- Upgrade
Axsome Therapeutics, Inc.'s stock has surged over 30% since my last “Hold” rating, driven by key catalysts like the litigation settlement with Teva Pharmaceuticals, announced today. Axsome's Auvelity and Sunosi are crucial, with Auvelity expected to generate over 75% of 2025 revenues; as such, today's news is a significant win. Despite high competition in MDD and other markets, Axsome's pipeline, including AXS-07 and AXS-12, shows potential for substantial revenue growth.
